Tumor‐Associated Macrophage Exosomal miR ‐142‐5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG /Ras/ ERK Axis
The FASEB Journal · 31.07.2026 · 40 (14)
DOI: 10.1096/fj.202600930r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 15.07.2026. Verfasst von Bo-Han Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: MicroRNAs, Exosomes, MAP Kinase Signaling System, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Technology Innovation Joint fund of Fujian Province, University-Industry Research Cooperation Project of Science and Technology, Fujian Province, Fujian Provincial Finance Department.
Abstract (Originalsprache)
Androgen deprivation therapy (ADT) for prostate cancer (PCa) leads to lineage plasticity in PCa cells, promoting the emergence of androgen receptor‐negative neuroendocrine prostate cancer (NEPC). NEPC is a highly aggressive subtype with poor prognosis and limited treatment options. Tumor‐associated macrophages (TAMs) contribute to tumor progression through exosome‐mediated communication. In our previous study, we analyzed RNA‐ s eq data to identify key genes involved in PCa progression, and the RERG gene emerged as a significant candidate that suppresses neuroendocrine differentiation (NED). In this study, we demonstrate that RERG expression is significantly reduced in CRPC cells and NEPC tissues, and its downregulation activates the Ras/ERK signaling pathway, which plays a crucial role in promoting NED. Additionally, miR‐142‐5p, transferred from TAMs via exosomes, downregulates RERG expression and activates the Ras/ERK pathway, thereby promoting PCa progression and NED. In vitro, miR‐142‐5p enhanced PCa cell proliferation, migration, invasion, and NED, while RERG overexpression reversed these effects. In vivo, RERG knockdown significantly promoted tumor growth and NED in a xenograft model. These findings highlight the role of TAM‐derived miR‐142‐5p in regulating NED and suggest that targeting the RERG/Ras/ERK axis may provide a novel therapeutic approach for NEPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Yong Wei
Förderung
- Science and Technology Innovation Joint fund of Fujian Province
- University-Industry Research Cooperation Project of Science and Technology, Fujian Province
- Fujian Provincial Finance Department
Zitieren
APA
Lin, B. H., Zhu, J. M., Kang, Z., Sun, J. B., Zhu, Z. H., Gao, R. C., Lin, B., Xu, N., Ke, Z. B., Zheng, Q. S., Xue, X. Y., & Wei, Y. (2026). Tumor‐Associated Macrophage Exosomal miR ‐142‐5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG /Ras/ ERK Axis. The FASEB Journal, 40(14). https://doi.org/10.1096/fj.202600930r
Vancouver
Lin BH, Zhu JM, Kang Z, Sun JB, Zhu ZH, Gao RC, et al. Tumor‐Associated Macrophage Exosomal miR ‐142‐5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG /Ras/ ERK Axis. The FASEB Journal. 2026;40(14). doi:10.1096/fj.202600930r
BibTeX
@article{Lin2026,
author = {Lin, Bo-Han and Zhu, Jun-Ming and Kang, Zhen and Sun, Jiang-Bo and Zhu, Zhong-Hua and Gao, Rui-Cheng and Lin, Bin and Xu, Ning and Ke, Zhi-Bin and Zheng, Qing-Shui and Xue, Xue-Yi and Wei, Yong},
title = {Tumor‐Associated Macrophage Exosomal miR ‐142‐5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG /Ras/ ERK Axis},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {14},
doi = {10.1096/fj.202600930r}
}
EUVIMED